JPWO2023054714A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2023054714A5 JPWO2023054714A5 JP2023551927A JP2023551927A JPWO2023054714A5 JP WO2023054714 A5 JPWO2023054714 A5 JP WO2023054714A5 JP 2023551927 A JP2023551927 A JP 2023551927A JP 2023551927 A JP2023551927 A JP 2023551927A JP WO2023054714 A5 JPWO2023054714 A5 JP WO2023054714A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- hydrophilic
- hydrogen atom
- hydrophilic group
- integer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 6
- 125000002843 carboxylic acid group Chemical group 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000000542 sulfonic acid group Chemical group 0.000 claims 4
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims 3
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims 3
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
- 235000013477 citrulline Nutrition 0.000 claims 3
- 229960002173 citrulline Drugs 0.000 claims 3
- 108010082974 polysarcosine Proteins 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 125000000524 functional group Chemical group 0.000 claims 2
- 125000003827 glycol group Chemical group 0.000 claims 2
- 238000002372 labelling Methods 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 239000003381 stabilizer Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025054423A JP2025098209A (ja) | 2021-09-30 | 2025-03-27 | 抗体および機能性物質の位置選択的なコンジュゲートまたはその塩、ならびにその製造に用いられる抗体誘導体および化合物またはそれらの塩 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021162299 | 2021-09-30 | ||
| JP2021162299 | 2021-09-30 | ||
| PCT/JP2022/036852 WO2023054714A1 (ja) | 2021-09-30 | 2022-09-30 | 抗体および機能性物質の位置選択的なコンジュゲートまたはその塩、ならびにその製造に用いられる抗体誘導体および化合物またはそれらの塩 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025054423A Division JP2025098209A (ja) | 2021-09-30 | 2025-03-27 | 抗体および機能性物質の位置選択的なコンジュゲートまたはその塩、ならびにその製造に用いられる抗体誘導体および化合物またはそれらの塩 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2023054714A1 JPWO2023054714A1 (https=) | 2023-04-06 |
| JPWO2023054714A5 true JPWO2023054714A5 (https=) | 2024-12-11 |
| JP7658450B2 JP7658450B2 (ja) | 2025-04-08 |
Family
ID=85780816
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023551927A Active JP7658450B2 (ja) | 2021-09-30 | 2022-09-30 | 抗体および機能性物質の位置選択的なコンジュゲートまたはその塩、ならびにその製造に用いられる抗体誘導体および化合物またはそれらの塩 |
| JP2025054423A Pending JP2025098209A (ja) | 2021-09-30 | 2025-03-27 | 抗体および機能性物質の位置選択的なコンジュゲートまたはその塩、ならびにその製造に用いられる抗体誘導体および化合物またはそれらの塩 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025054423A Pending JP2025098209A (ja) | 2021-09-30 | 2025-03-27 | 抗体および機能性物質の位置選択的なコンジュゲートまたはその塩、ならびにその製造に用いられる抗体誘導体および化合物またはそれらの塩 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240269311A1 (https=) |
| EP (1) | EP4410831A1 (https=) |
| JP (2) | JP7658450B2 (https=) |
| KR (1) | KR20240073034A (https=) |
| CN (1) | CN118119640A (https=) |
| AU (1) | AU2022353331A1 (https=) |
| CA (1) | CA3234689A1 (https=) |
| WO (1) | WO2023054714A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024206573A2 (en) * | 2023-03-29 | 2024-10-03 | Exelixis, Inc. | Amhrii antibody-drug conjugates and uses thereof |
| WO2026076215A1 (en) * | 2024-10-03 | 2026-04-09 | Solve Therapeutics, Inc. | Conjugates and uses thereof |
| WO2026085106A1 (en) * | 2024-10-15 | 2026-04-23 | Solve Therapeutics, Inc. | Conjugates and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
| EP2478912B1 (en) | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| US9089614B2 (en) * | 2012-12-21 | 2015-07-28 | Bioalliance C.V. | Hydrophilic self-immolative linkers and conjugates thereof |
| JP2015038426A (ja) | 2013-07-04 | 2015-02-26 | 株式会社阪本商会 | 液体定量抽出具 |
| WO2015038426A1 (en) | 2013-09-13 | 2015-03-19 | Asana Biosciences, Llc | Self-immolative linkers containing mandelic acid derivatives, drug-ligand conjugates for targeted therapies and uses thereof |
| AU2018259856B2 (en) | 2017-04-28 | 2025-05-01 | Ajinomoto Co., Inc. | Compound having substance that has affinity for soluble protein, cleavable moiety, and reactive group, or salt thereof |
| MX2020012674A (es) * | 2018-05-29 | 2021-02-09 | Bristol Myers Squibb Co | Porciones autoinmolantes modificadas para usarse en profarmacos y conjugados y metodos de uso y fabricacion. |
| KR102921757B1 (ko) | 2018-06-14 | 2026-02-03 | 아지노모토 가부시키가이샤 | 항체에 대한 친화성 물질, 절단성 부분 및 반응성기를 갖는 화합물 또는 이의 염 |
| JPWO2019240288A1 (ja) | 2018-06-14 | 2021-07-26 | 味の素株式会社 | 抗体に対する親和性物質、および生体直交性官能基を有する化合物またはその塩 |
| JPWO2020090979A1 (ja) | 2018-10-31 | 2021-09-24 | 味の素株式会社 | 抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩 |
| JP7110955B2 (ja) | 2018-12-04 | 2022-08-02 | トヨタ自動車株式会社 | インホイールモータ |
| EP3970752A1 (en) * | 2020-09-17 | 2022-03-23 | Merck Patent GmbH | Molecules with solubility tag and related methods |
-
2022
- 2022-09-30 AU AU2022353331A patent/AU2022353331A1/en active Pending
- 2022-09-30 CA CA3234689A patent/CA3234689A1/en active Pending
- 2022-09-30 KR KR1020247010602A patent/KR20240073034A/ko active Pending
- 2022-09-30 CN CN202280066825.6A patent/CN118119640A/zh active Pending
- 2022-09-30 WO PCT/JP2022/036852 patent/WO2023054714A1/ja not_active Ceased
- 2022-09-30 EP EP22876576.4A patent/EP4410831A1/en active Pending
- 2022-09-30 JP JP2023551927A patent/JP7658450B2/ja active Active
-
2024
- 2024-03-28 US US18/619,756 patent/US20240269311A1/en active Pending
-
2025
- 2025-03-27 JP JP2025054423A patent/JP2025098209A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2023054714A5 (https=) | ||
| DE69730332T2 (de) | Alkyldextran-polyalcohol Arzneimittel-Komplexe | |
| JP2023534437A5 (https=) | ||
| US8257682B2 (en) | Compositions for delivery of therapeutics and other materials | |
| DE69416116T2 (de) | Effektorenhaltige mittel mit verlängerter zirkulationsdauer sowie verfahren | |
| KR910005887B1 (ko) | 약물-모노클로날 항체 결합체 | |
| JP6762094B2 (ja) | 薬剤のデリバリーのためのジスルフィド化合物 | |
| IL312845B1 (en) | Extacan derivatives, charge-linkers, and their conjugates | |
| US11299509B2 (en) | Trigger-activatable sugar conjugates for cancer-selective labeling and targeting | |
| TW202214230A (zh) | 一種抗腫瘤化合物及其製備方法和應用 | |
| JP2009073832A (ja) | モノマー性カリキアミシン誘導体／キャリアー複合体の製造方法 | |
| WO1991013100A1 (en) | Cyclodextrin compositions and methods for pharmaceutical and industrial applications | |
| JPH02196864A (ja) | ポリマー錯体、その製法、これを含有するｎｍｒ‐、レントゲン‐又は超音波‐診断剤 | |
| US20250179015A1 (en) | Degradable lipid for active molecule delivery and lipid nanoparticle thereof | |
| US6194543B1 (en) | Dendritic polypeptides | |
| FR2736056A1 (fr) | Derives de cyclodextrines, leur preparation et leur utilisation pour incorporer des molecules hydrophobes dans des systemes de tensioactifs organises | |
| JP2626654B2 (ja) | 標的指向性高分子医薬化合物及びその中間体 | |
| CN113365969B (zh) | 含有邻苯二甲醛的连接体及其用于制备抗体-药物缀合物的用途 | |
| JP2024524363A5 (https=) | ||
| CN111643678A (zh) | 基于含巯基的两性离子多肽修饰的阿霉素衍生物、纳米胶束及其制备方法 | |
| JPWO2023054706A5 (https=) | ||
| JP2024521092A5 (https=) | ||
| WO2022154127A1 (ja) | 化合物またはその塩、およびそれらにより得られる抗体 | |
| JP2024540097A5 (https=) | ||
| JP2025500404A5 (https=) |